| Excerpt | Reference |
|---|
| "In a transient middle cerebral artery occlusion model in rats, clomethiazole was administered subcutaneously over 22." | ( Cross, AJ; Green, AR; Jones, JA; Murray, TK; Sydserff, SG, 2000) |
| "Rats were subjected to 2 hours of middle cerebral artery occlusion followed by 22 hours of reperfusion under the following protocols: (1) rats were treated with normothermia (37." | ( Kawai, N; Morisaki, K; Nagao, S; Okauchi, M, 2000) |
| "Stroke volume after 1-hour middle cerebral artery occlusion/23-hour reperfusion was significantly reduced by 38% in atorvastatin-treated animals (10 mg/kg) compared with controls." | ( Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Huang, P; Laufs, U; Nickenig, G, 2000) |
| "In the rat middle cerebral artery occlusion model, intracarotid administration of proliNO (10(-5) mol/L) (n = 10) during reperfusion reduced the brain infarction volume from 256 +/- 48 mm3 in the vehicle-treated group (n = 8) to 187 +/- 41 mm3 (P < 0." | ( Khaldi, A; Oldfield, EH; Pluta, RM; Rak, R; Watson, JC; Wink, DA; Woodward, JJ, 2001) |
| "Patients with large middle cerebral artery infarction and elevated intracranial pressure (ICP) who are undergoing invasive intensive care therapy require technical monitoring." | ( Aschoff, A; Friederichs, V; Hacke, W; Pilz, J; Schellinger, P; Steiner, T; Wirtz, R, 2001) |
| "By using a rat model of middle cerebral artery occlusion (MCAO), we tested the hypothesis that significant edema occurs in the contralateral uninjured hemisphere and that this postischemic complication can be manipulated by hypertonic saline therapy." | ( Bhardwaj, A; Hurn, PD; Toung, TJ; Traystman, RJ, 2002) |
| "After 90 min of transient middle cerebral artery occlusion in male rats the expression of FKBP12, 52 and 65 was analyzed by Western blot in FK506-treated and control animals and the peptidyl-prolyl cis/trans isomerase activity was determined." | ( Brecht, S; Christner, C; Fischer, G; Heiland, S; Herdegen, T; Sartor, K; Schwarze, K; Waetzig, V, 2003) |
| "In the subtemporal middle cerebral artery occlusion (MCAO) model of focal ischemia, intracerebroventricular (icv) administration of IGF-I and IGF-II at the time of artery occlusion reduced ischemic brain damage in a dose-dependent manner, with maximum reductions in total infarct size of 37% (P < 0." | ( Foster, AC; Loddick, SA; Mackay, KB; Naeve, GS; Vana, AM; Verge, GM, 2003) |
| "In the present study, transient middle cerebral artery occlusions (MCAO) were induced for various duration, and protective effects of estrogen treatment on the cerebral cortex and subcortex were evaluated." | ( Day, AL; Fan, T; Hayes, R; Johnson, E; Osteen, B; Simpkins, JW; Yang, SH, 2003) |
| "Nineteen patients suffering from acute middle cerebral artery occlusion (Thrombolysis in Myocardial Infarction [TIMI] flow grade 0 to 1) underwent combined intravenous thrombolytic treatment using rtPA at reduced dosages and the GPIIb/IIIa antagonist tirofiban." | ( Jovanovic, V; Junghans, U; Seitz, RJ; Siebler, M; Straub, S; Wittsack, HJ, 2004) |
| "At 6 hrs following middle cerebral artery occlusion, rats were treated in a blinded randomized fashion with no intravenous fluids (n = 24), a continuous intravenous infusion (0." | ( Bhardwaj, A; Chang, Y; Lin, J; Toung, TJ, 2005) |
| "In the permanent middle cerebral artery occlusion model, repinotan showed neuroprotective efficacy when administered as a triple bolus injection (0." | ( Horváth, E; Mauler, F, 2005) |
| "Twenty-four hours after permanent middle cerebral artery occlusion, propofol (100 mg/kg, intraperitoneal) reduced the infarct size by approximately 30% when administered immediately after and up to 30 min after the occlusion." | ( Adembri, C; Chiarugi, A; Cozzi, A; De Gaudio, RA; Gramigni, E; Pancani, T; Pellegrini-Giampietro, DE; Tani, A; Venturi, L, 2006) |
| "thiamine administration reduced the middle cerebral artery occlusion-induced infarct." | ( Sheline, CT; Wei, L, 2006) |
| "Rats were subjected to middle cerebral artery occlusion and treated with or without atorvastatin (3 mg/kg) for 7 days." | ( Chen, J; Chopp, M; Ding, J; Kapke, A; Li, A; Lu, M; Roberts, C; Zacharek, A; Zhang, C, 2006) |
| "Four days after temporary middle cerebral artery occlusion, minocycline was administered intraperitoneally for 4 weeks." | ( Fan, Y; Hu, D; Liu, J; Liu, Z; Neumann, M; Weinstein, PR; Won, SJ; Zhou, L, 2007) |
| "Rats subjected to embolic middle cerebral artery occlusion (MCAo) were treated with rhEPO or CEPO, starting at 6 h and repeated at 24 and 48 h, after MCAo." | ( Chopp, M; Heavner, G; Kapke, A; Lu, M; Pool, C; Renzi, M; Rhodes, K; Wang, Y; Zhang, RL; Zhang, ZG, 2007) |
| "Rats exposed to permanent middle cerebral artery occlusion were treated for 3 months with fluvastatin beginning from 7 days after stroke." | ( Hayashi, T; Iida, H; Kurinami, H; Morishita, R; Sata, M; Sato, N; Shimamura, M; Takeuchi, D; Wakayama, K, 2007) |
| "A temporary middle cerebral artery occlusion (tMCAO) model was used in 80 Wistar rats to evaluate whether a high dose of Aspirin (40 mg/kg) applied with different initiation time points after stroke onset (30 min, 3 h, 6 h, 12 h, 20 rats for each time group) and followed by repeated administration (1, 2 and 3 days) is neuroprotective." | ( Berger, C; Grau, A; Schwab, S; Zheng, Z, 2007) |
| "Animals underwent 90 min of middle cerebral artery occlusion (MCAO) followed by 90 min of reperfusion before oxygen treatment." | ( Carl, UM; Deuschl, G; Eschenfelder, CC; Herdegen, T; Koch, A; Krug, R; Meyne, JK; Yusofi, AF; Zhao, Y, 2008) |
| "Mice subjected to 2-h filamental middle cerebral artery occlusion were treated with NBO (95% O2, during the ischemia) alone, with edaravone (1." | ( Hara, H; Iwama, T; Nonaka, Y; Shimazawa, M; Yoshimura, S, 2008) |
| "Adult rats underwent middle cerebral artery occlusion, received BrdU on days 5-11 after stroke and were treated with RA/EE, RA alone, EE/vehicle or vehicle alone and were killed 61 days after stroke." | ( Parent, JM; Plane, JM; Schallert, T; Whitney, JT, 2008) |
| "Rats subjected to 2 hours of middle cerebral artery occlusion (MCAO) were randomly assigned to four groups: Group 1, IN administration of phosphate-buffered saline (PBS) for control; Group 2, IN administration of NGF alone; Group 3, EA with IN administration of PBS; Group 4, IN administration of NGF with EA." | ( Cheng, S; Liu, X; Ma, M; Ma, Y; Wang, Z; Xu, G, 2009) |
| "Male Wistar rats were subjected to middle cerebral artery occlusion and treated with recombinant human erythropoietin intraperitoneally at a dose of 5000 U/kg of body weight (n=11) or the same volume of saline (n=7) daily for 7 days starting 24 hours after middle cerebral artery occlusion." | ( Chopp, M; Ding, G; Ewing, JR; Jiang, Q; Kapke, A; Li, L; Li, Q; Lu, M; Panda, S; Zhang, L; Zhang, ZG, 2009) |
| "Rats were subjected to middle cerebral artery occlusion and were treated with or without Niaspan." | ( Chen, J; Chopp, M; Cui, X; Ding, GL; Jiang, Q; Lu, M; Shehadah, A; Zacharek, A, 2009) |
| "Animals were treated with permanent middle cerebral artery occlusion followed by an 18 day CUMS procedure." | ( Guo, YJ; Sui, YX; Sun, Y; Wang, SH; Zhang, ZJ, 2009) |
| "C57BL/6J mice were subjected to middle cerebral artery occlusion and were treated with or without TO901317 (30 mg/kg) starting 24 hours after middle cerebral artery occlusion and daily for 14 days." | ( Chen, J; Chopp, M; Cui, X; Roberts, C; Zacharek, A, 2009) |
| "Animals were subjected to middle cerebral artery occlusion (MCAO) for 2h and treated with 1." | ( Aguilera, P; Barrera, D; Chánez-Cárdenas, ME; Espinoza-Rojo, M; León-Aparicio, D; Maldonado, PD; Ortiz-Plata, A; Sánchez-García, A; Villeda-Hernández, J, 2010) |
| "Sixty SD rats with middle cerebral artery occlusion (MCAO) were randomly divided into untreated group and scalp acupuncture group." | ( Li, X; Liu, LG; Liu, YN; Wang, Q; Yang, M; Yang, X; Zhang, HX; Zhou, L, 2009) |
| "We performed middle cerebral artery occlusion in postnatal day 10 rats, which were treated with either a single dose of EPO (5 U/g, i." | ( Abel, R; Almli, CR; Ferriero, DM; Gonzalez, FF; Mu, D; Wendland, M, 2009) |
| "For a mouse model of middle cerebral artery occlusion, oral administration with DCP-LA (1 mg/kg) significantly diminished degraded area due to cerebral infarction." | ( Fujikawa, H; Nishizaki, T; Yaguchi, T, 2010) |
| "We used a middle cerebral artery occlusion (MCAO) model and administered OMT intraperitoneally immediately after cerebral ischemia and once daily on the following days." | ( Fan, H; Li, L; Liu, Y; Yang, C; Yang, Y; Yin, J; Zhang, X, 2009) |
| "Adult male rats were subjected to 2 h middle cerebral artery occlusion (MCAo) and treated with or without Niaspan alone, Simvastatin alone and combination Niaspan and Simvastatin starting 24 h after MCAo and daily for 14 days." | ( Chen, J; Chopp, M; Cui, X; Lu, M; Roberts, C; Shehadah, A, 2010) |
| "Before middle cerebral artery occlusion, they were administered telmisartan or losartan, with or without GW9662, a PPAR-gamma antagonist, for 2 weeks." | ( Horiuchi, M; Iwai, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2010) |
| "Male SD rats received right middle cerebral artery occlusion for 120 min and AST (40 mg/kg) was orally administered." | ( Gong, HL; Li, WP; Li, WZ; Wu, GC; Yin, YY; Zhu, FF, 2010) |
| "Male mice were subjected to middle cerebral artery occlusion after acute (3 days) or chronic (3 weeks) administration of metformin." | ( Benashski, SE; Li, J; McCullough, LD; Venna, VR, 2010) |
| "Male Lewis rats underwent 3 hours middle cerebral artery occlusion and were treated with lipopolysaccharide or saline at the time of reperfusion." | ( Becker, KJ; Carter, KT; Hadwin, J; Kunze, A; Savos, A; Zierath, D, 2010) |
| "Mice subjected to 6-h middle cerebral artery occlusion were treated with delayed tPA alone at 6 h, with combined tPA plus cilostazol at 6 h, or with vehicle at 6 h." | ( Chen, H; Fujiwara, Y; Hara, H; Ishiguro, M; Iwama, T; Izuta, H; Mishiro, K; Satoh, M; Shimazawa, M; Tsuruma, K; Yoshimura, S, 2010) |
| "Here, using a rat model of permanent middle cerebral artery occlusion (MCAO), we demonstrated that administration of LA 30 min prior to stroke, reduces infarct volume in a dose dependent manner." | ( Connell, BJ; Khan, BV; Richard, MJ; Saleh, TM, 2011) |
| "Adult male rats were subjected to 2-h middle cerebral artery occlusion and then assigned to 1 of 4 inhaled gas exposure groups: I: 70%/30% nitrogen/oxygen (control); II: 70%/30% helium/oxygen administered immediately after occlusion; III: 70%/30% helium/oxygen administered after a 30-60 min delay; or, IV: 40%/30%/30% nitrogen/helium/oxygen administered immediately after occlusion." | ( Acharya, AB; Cruz-Flores, S; Pan, Y; Panneton, WM; Zhang, H, 2011) |
| "Following transient middle cerebral artery occlusion, progesterone was administered at 1, 6 and 24 h post-ischaemia to aged and ovariectomized female mice." | ( Coomber, B; Gibson, CL; Murphy, SP, 2011) |
| "Rats that were exposed to permanent middle cerebral artery occlusion (MCAO) and treated with intravenous 250 mg/kg pyruvate had a smaller volume of infarction and reduced brain edema, resulting in an improved neurological outcome and reduced mortality compared to control rats treated with saline." | ( Boyko, M; Gruenbaum, BF; Gruenbaum, SE; Kuts, R; Melamed, I; Ohayon, S; Regev, A; Shapira, Y; Teichberg, VI; Zlotnik, A, 2011) |
| "T1DM-rats were subjected to transient middle cerebral artery occlusion (MCAo) and treated without or with Niaspan." | ( Chen, J; Chopp, M; Cui, X; Cui, Y; Liu, X; Lu, M; Roberts, C; Shehadah, A; Yan, T; Ye, X; Zacharek, A, 2011) |
| "T1DM rats were subjected to 2h transient middle cerebral artery occlusion (MCAo) and were treated with 40 mg/kg Niaspan or saline starting 24 h after MCAo and daily for 28 days." | ( Buller, B; Chen, J; Chopp, M; Cui, Y; Liu, Z; Roberts, C; Yan, T; Ye, X; Zacharek, A, 2012) |
| "Mice were subjected to transient middle cerebral artery occlusion (tMCAO) for 60 min and divided into the following four groups by intravenous administration upon reperfusion, vehicle, tPA, tPA+nPt, and nPt." | ( Abe, K; Deguchi, K; Miyamoto, Y; Ohta, Y; Takamiya, M; Yamashita, T, 2012) |
| "Treatment of the middle cerebral artery occlusion (MCAo)-induced animals with PEA reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride (TTC) staining across brain sections." | ( Ahmad, A; Crupi, R; Cuzzocrea, S; Esposito, E; Genovese, T; Impellizzeri, D; Marino, A; Velardi, E, 2012) |
| "In rat models of permanent and temporary middle cerebral artery occlusion, the ischemic cerebral hemispheres displayed endothelial and neuronal apoptosis next to increased endothelial NP-1 and VEGFR-2 expression compared to non-ischemic cerebral hemispheres, sham-operated or untreated controls." | ( Al-Fakhri, N; Dönges, S; Gassmann, M; Gerriets, T; Hörmann, M; Kinscherf, R; Mey, L; Reuter, P; Schleicher, N, 2013) |
| "Male Sprague-Dawley rats underwent middle cerebral artery occlusion and reperfusion, followed by intraperitoneal or intravenous treatment of sildenafil starting 2 h later." | ( Chen, XM; Wang, F; Wang, NN; Wu, CF; Yang, JY; Zhang, TY, 2014) |
| "Experiments using the permanent middle cerebral artery occlusion (MCAO) rat model were carried out to determine if afobazole can reduce ischemic stroke damage in vivo and expand the therapeutic window for stroke treatment." | ( Behensky, AA; Cuevas, J; Garcia, A; Katnik, C; McAleer, J; Petrov, AV; Seifu, S; Seredenin, SB; Shuster, AM; Willing, A; Yasny, IE, 2014) |
| "Three weeks after middle cerebral artery occlusion (MCAO), rats were treated with E2 for consecutive 14 days." | ( Cheng, J; Cheng, Y; Jin, K; Lin, Z; Ruan, L; Shao, B; Su, Q; Wang, H; Wang, L; ZhuGe, Q, 2013) |
| "Sprague-Dawley rats underwent permanent middle cerebral artery occlusion, then received treatment with propofol (10 or 50 mg/kg) or vehicle after 2 h of ischemia." | ( Chen, JP; Chen, Y; Shi, SS; Tu, XK; Yang, WZ, 2014) |
| "One week after middle cerebral artery occlusion, the animals received stereotactic injection of adenoassociated virus (AAV) carrying SDF-1α gene as treatment or AAV-green fluorescent protein as control and were monitored for 5 weeks." | ( He, X; Huang, J; Li, Y; Lin, X; Liu, Y; Lu, Y; Tang, G; Tang, YH; Wang, Y; Yang, GY, 2014) |
| "We used a middle cerebral artery occlusion (MCAO) model of cerebral ischemia, associated with treatment with tPA, in male spontaneously hypertensive rats (SHR)." | ( Bordet, R; Dupont, A; Gautier, S; Laprais, M; Lefebvre, C; Leys, D; Ouk, T; Pétrault, O; Tagzirt, M, 2014) |
| "Sprague-Dawley rats were subjected to middle cerebral artery occlusion (MCAO) model, and morroniside was then administered intragastrically once a day at doses of 30, 90, and 270 mg/kg." | ( Ai, HX; Cheng, H; Ji, XM; Li, L; Sun, FL; Wang, W; Wang, XF; Wang, XM; Wang, Y; Xu, JD; Xue, JL; Zhang, L, 2014) |
| "Transient middle cerebral artery occlusion (MCAO) was induced for 3h using an intraluminal suture in warfarin-treated mice to produce hemorrhagic transformation." | ( Fujimura, M; Hasumi, K; Ito, A; Niizuma, K; Shimizu, H; Tominaga, T, 2014) |
| "Male Sprague-Dawley rats underwent middle cerebral artery occlusion, followed by intraperitoneal or intravenous treatment with yonkenafil starting 2h later." | ( Chen, X; Liu, Y; Wang, N; Wang, Y; Wu, C; Yang, J; Zhang, T; Zhu, L, 2014) |
| "I/R insult was induced by 2 h middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion; Drugs were administered 20 min before the onset of ischemia and continued for another 2 h." | ( Du, H; He, Y; Kou, D; Li, Z; Wang, Z; Yu, W, 2014) |
| "Male rats which underwent permanent middle cerebral artery occlusion were treated with a combination of estradiol/progesterone at 6, 24 and 48 h after injury and sacrificed at 54 h post-ischemia." | ( Alonso, A; Mateos, L; Perez-Alvarez, MJ; Wandosell, F, 2015) |
| "TSA treatment after middle cerebral artery occlusion, markedly reduced infarct size, and reduced the expression of caspase-3 and caspase-8." | ( Bondy, SC; Jian, L; Li, W; Luo, H; Wen, P; Yang, F; Zhou, J; Zhou, L, 2015) |
| "C57/BL6J mice were subjected to middle cerebral artery occlusion, followed by reperfusion, and IVIg was administered intravenously 3 h after the start of reperfusion." | ( Arumugam, TV; Basta, M; Lok, KZ; Manzanero, S, 2015) |
| "In this study, rats were subjected to middle cerebral artery occlusion prior to treatment with 5 % HS bolus +5 % HS maintenance (HS), conivaptan alone (Con), conivaptan +5 % HS maintenance (Con + HS), or conivaptan +5 % HS bolus +5 % maintenance (Con + HSb)." | ( Collier, L; Decker, D; Lau, T; Leonardo, C; Olivera, R; Pennypacker, KR; Roma, G; Rowe, D; Seifert, H, 2016) |
| "Sprague-Dawley rats were subjected to a middle cerebral artery occlusion (MCAO) model of ischemic stroke and then were administered rtPA, rtPA combined with TWS119, or vehicle at 4 h." | ( Chen, Q; Deng, G; Li, M; Li, Q; Wan, J; Wang, J; Wang, W; Wang, Y; Yang, Q, 2016) |
| "To this end, rats were treated with middle cerebral artery occlusion (MCAO) followed by chronic unpredictable mild stress (CUMS) treatment procedure." | ( Guan, J; Jia, J; Liu, S; Sun, H; Wang, S; Wang, T, 2016) |
| "For the 60-min middle cerebral artery occlusion (MCAO), NBO treatment for 25 min and 150 min were studied." | ( Du, F; Duong, TQ; Jiang, Z; Rodriguez, P; Shen, Q; Sun, Y; Tiwari, YV, 2016) |
| "Rats with middle cerebral artery occlusion, in accordance with the random number table, were divided into four groups: (1) the rats in Cilengitide group A (n=30) were treated with Cilengitide at a dose of 100 μg/kg; (2) the rats in Cilengitide group B (n=28) were treated with Cilengitide at a dose of 200 μg/kg; (3) the rats in sham group (n=31), without inserting thread into middle cerebral artery, were treated with normal saline; (4) the rats in control group (n=27) were treated with normal saline." | ( Fang, T; Lu, LQ; Tong, XX; Wu, J; Yi, L; Zhou, D, 2016) |
| "Rats were subjected to right middle cerebral artery occlusion through electrocoagulation and were treated with catalpol (5mg/kg), AG490 was also used to inhibit STAT3 phosphorylation (pSTAT3)." | ( Dong, W; Hongli, W; Hongyi, Q; Huifeng, Z; Jinghuan, W; Lei, Q; Li, Z; Shan, F; Tao, W; Xian, Y; Ya, F; Yuan, W; Zhiqiang, L, 2016) |
| "Adult male Sprague-Dawley rats underwent middle cerebral artery occlusion (MCAO), then received treatment with zileuton or vehicle after the onset of ischemia." | ( Chen, CM; Liang, RS; Shi, SS; Tu, XK; Wang, CH; Yang, WZ; Zhang, HB, 2016) |
| "Rats with transient (60 min) MCAO (middle cerebral artery occlusion) were treated with: (1) air + vehicle (N = 8), (2) air + MB (N = 8), (3) NBO + vehicle (N = 7), and (4) NBO + MB (N = 9)." | ( Duong, TQ; Milman, B; Rodriguez, P; Tiwari, YV; Zhao, J, 2016) |
| "We developed a protocol in which middle cerebral artery occlusion was combined with catheter installation into the jugular vein for IV treatment of conivaptan (0." | ( Elliott, JP; Jones, SM; Zeynalov, E, 2016) |
| "Mice subjected to transient middle cerebral artery occlusion/reperfusion (tMCAO/R) were administered with vehicle or D3T to evaluate the effect of D3T in cerebral brain injury." | ( Brown, DA; Chang, FL; Curfman, ET; Kuo, PC; Paraiso, HC; Scofield, BA; Yen, JH; Yu, IC, 2017) |
| "Two-hour middle cerebral artery occlusion rats were immediately subjected to intra-arterial infusion of LEH (LEH group) or saline (vehicle group) or no treatment (control group), and then to recanalization." | ( Abumiya, T; Houkin, K; Kazumata, K; Kurisu, K; Nakamura, H; Nakayama, N; Osanai, T; Shichinohe, H; Shimbo, D; Shimuzu, H, 2017) |
| "In the transient middle cerebral artery occlusion (MCAO) mice model, The engineered c(RGDyK)-conjugated exosomes (cRGD-Exo) target the lesion region of the ischemic brain after intravenous administration." | ( Fan, S; Gao, J; He, CP; Huang, NP; Lu, ZH; Qi, C; Tannous, BA; Tian, T; Xiao, ZD; Zhang, HX; Zhu, YL, 2018) |
| "Left middle cerebral artery occlusion (MCAO) was performed to generate the rat model of ischemic stroke, followed by daily RIPostC treatment for maximum 21 days." | ( Bai, YL; Gao, BY; He, XB; Li, C; Liang, D; Wang, Z; Wu, JF, 2018) |
| "Adult male Sprague Dawley rats receiving middle cerebral artery occlusion surgery as animal model of cerebral ischemia/reperfusion injury were randomly assigned to 4 groups: control, resveratrol alone pretreatment, rosuvastatin alone pretreatment, and combined rosuvastatin and resveratrol pretreatment." | ( Bi, J; Chen, H; Jia, G; Li, L; Liu, Y; Wang, C; Yang, H, 2018) |
| "Rats were subjected to 3 h of middle cerebral artery occlusion (MCAO) and were intraperitoneally administered with 10, 20 or 40 mg/kg SALD before ischemia." | ( Hu, X; Mei, D; Yan, F; Zhang, B; Zuo, W, 2018) |
| "Rats subjected to embolic middle cerebral artery occlusion were treated with taurine (50 mg/kg) at 4 hours in combination with tPA (10 mg/kg) at 6 hours." | ( Jin, R; Li, G; Liu, S; Wang, M; Xiao, AY, 2018) |
| "In this study, we established a model of middle cerebral artery occlusion (MCAO) and treated primary cortical neurons with oxygen glucose deprivation (OGD), followed by Dex treatment." | ( Fang, T; Fu, Q; Liu, C; Mu, R; Tian, F; Wang, F; Yu, B; Zhang, L; Zhang, Y; Zhou, C, 2018) |
| "ICR mice were subjected to transient middle cerebral artery occlusion (tMCAO) for 60 min, SMTP-44D (10 mg/kg) or edaravone (3 mg/kg) was intravenously administrated through subclavian vein just after the reperfusion, and these mice were examined at 1, 3, and 7 d after reperfusion." | ( Abe, K; Feng, T; Fukui, Y; Hasumi, K; Hishikawa, N; Huang, Y; Liu, X; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Shang, J; Shi, X; Suzuki, E; Takemoto, M; Yamashita, T, 2018) |
| "Rats were subjected to 1 hour of middle cerebral artery occlusion (MCAO) and treated with celecoxib 1 and 24 hours after ischemia." | ( Anuncibay-Soto, B; Fernández-López, A; Font-Belmonte, E; Pérez-García, CC; Pérez-Rodríguez, D; Santos-Galdiano, M; Ugidos, IF, 2018) |
| "In a murine middle cerebral artery occlusion (MCAO) stroke model, administration of alogliptin ameliorated cerebral infarction and disruption of brain vascular permeability, and restored expression of the endothelial tight junction proteins occludin and zona occludens 1 (ZO-1)." | ( Guo, AH; Han, XF; Hao, FL; Lu, XJ; Wang, XL; Zhao, XF; Zhao, ZR, 2019) |
| "Mice were subjected to transient middle cerebral artery occlusion and PNS were administrated to mice 3 days before and 2 days after surgery." | ( Dong, S; Han, B; Jia, Z; Liang, Y; Sun, J; Wu, T; Zhang, R; Zhang, S, 2019) |
| "In vivo, 2 h of middle cerebral artery occlusion (MCAO) model was established, followed with reperfusion and GB treatments for 24 and 72 h." | ( Cao, L; Gu, S; Jin, Z; Li, F; Li, G; Li, L; Liu, Q; Wang, Z; Xiao, W; Xu, Z; Yang, H; Zhou, J; Zong, S, 2019) |
| "IRI was simulated in a rat model by middle cerebral artery occlusion (MCAO) surgery, and the animals were treated with different doses of hispidulin." | ( An, P; Li, L; Liu, Y; Qiu, S; Tang, M; Wang, J; Xie, J; Xiu, X, 2019) |
| "Following middle cerebral artery occlusion/reperfusion (MCAO/R) surgery, rats were treated orally with 32, 16, and 8 mg/kg AR respectively for 14 days during which cerebral injury was evaluated and proinflammatory factors tumor necrosis factor-α and interleukin-6 as well as neurotrophic factors brain-derived neurotrophic factor and Neurotrophin-3 levels were determined with ELISA kits." | ( Chen, S; Fang, W; Hou, K; Hu, Y; Li, F; Li, Y; Xia, N; Xu, D, 2019) |
| "Rats were divided into 4 groups: sham, middle cerebral artery occlusion, middle cerebral artery occlusion + baicalin, middle cerebral artery occlusion + baicalin treated + inhibitor (bromocriptine, which inhibit progesterone induction)." | ( Guo, Y; Li, H; Liu, T; Pan, Y; Wang, D; Wu, L, 2019) |
| "Here, we treated the transient middle cerebral artery occlusion (tMCAO) mice with DMI or saline at the beginning of occlusion, and allowed them to recover for 3 days." | ( Guo, R; Liu, C; Lu, Z; Man, J; Wang, J; Zhang, D; Zhang, Z, 2019) |
| "We used the murine suture middle cerebral artery occlusion (MCAO) models of stroke followed by delayed administration of tPA (10 mg/kg, 2 hours after suture occlusion) to investigate the therapeutic potential of RSG against tPA-induced HT." | ( Chen, ZA; Huang, TT; Li, PY; Li, Y; Lu, BW; Wen, DX; Xuan, W; Yu, WF; Zhang, YM; Zhou, NY; Zhu, ZY, 2019) |
| "In the middle cerebral artery occlusion and reperfusion (MCAO/R) model of mice, probucol administration after MCAO operation reduced the infarction area and vascular leakage, preserving the integrity of tight junction proteins." | ( Aruga, J; Nakagawa, S, 2020) |
| "In a rat model with transient middle cerebral artery occlusion (MCAO), post-insult intraventricular medium B treatment enhanced proliferation, migration, and neuronal differentiation of NSPCs and diminished cell apoptosis in the infarct brain." | ( Chen, YA; Chen, YD; Liu, DZ; Tsai, LK; Tsai, YC; Young, TH, 2020) |
| "The rats underwent middle cerebral artery occlusion (MCAO) surgery and oxygen-glucose deprivation (OGD)-treated HT22 hippocampal neurons were treated with DEX, respectively." | ( Du, H; Guo, H; Hu, Z; Liu, W; Lv, J; Wang, L; Zhang, Y, 2020) |
| "In transient middle cerebral artery occlusion (tMCAO) rats, intraarterial administration of RES-NPs demonstrated significant protection against cerebral ischemia/reperfusion (I/R) injuries." | ( Ding, D; Dong, J; Li, X; Lu, X; Xu, H; Zheng, D, 2020) |
| "Cerebral I/R injury was induced by middle cerebral artery occlusion (MCAO), and the treatment groups were administered ICS II at a dose of 16 mg/kg by gavage twice a day for 3 days." | ( Gao, JM; Gong, QH; Li, F; Liu, MB; Shi, JS; Wang, W, 2020) |
| "Cerebral I/R model was established with middle cerebral artery occlusion method in Sprague Dawley rats and then rats were treated with DHAG (1 and 2 mg/kg) for 7 days." | ( Du, R; Li, Q; Lin, F; Yang, D; Zhou, H; Zhou, X, 2020) |
| "Mice were subjected to middle cerebral artery occlusion (MCAO) model to induce IS injures and then were administrated with VPA." | ( Li, X; Sui, Y, 2020) |
| "Transient middle cerebral artery occlusion (tMCAO) was used as a mouse model of ischemic stroke, while BV2 cells stimulated with conditioned medium collected from oxygen-glucose deprivation-treated HT22 cells were used in in vitro ischemic studies." | ( Chen, C; Du, JR; Duan, W; Gan, YM; Liu, DL; Yang, YX, 2020) |
| "The rats were submitted to middle cerebral artery occlusion (MCAO) and were treated with sodium butyrate or Myricitrin (15 and 30 mg/kg) for 28 days." | ( Gao, Y; Guo, Y; Li, X; Ya, B; Yin, H, 2021) |
| "Rats were used to conduct middle cerebral artery occlusion (MCAO) model and were treated with different dosage of Z-GS." | ( Ding, Y; Feng, X; Guo, C; Liu, M; Liu, T; Ma, Y; Mu, F; Wang, W; Wen, A; Zhang, Y, 2020) |
| "Transient middle cerebral artery occlusion or sham surgery was performed in postnatal day (P) 10 Sprague-Dawley rats, who were treated with single-dose intranasal MSC, MSC preexposed to EPO (MSC/EPO), multidose systemic EPO (EPO3; 1000 u/kg per dose×3 every 72 hours), or cell-conditioned media on P13 (day 3 [P13-P19] for EPO), or on P17 (day 7 [P17-P23] for EPO)." | ( Ferriero, D; Gonzalez, FF; Larpthaveesarp, A; Ostrin, S; Pathipati, P; Rajah, A, 2021) |
| "Using a transient middle cerebral artery occlusion (tMCAo) rodent model of stroke, we studied two rat cohorts, one without rt-PA and a second cohort treated with rt-PA." | ( Igarashi, T; Kimberly, WT; Sastre, C; Wolcott, Z, 2021) |
| "A rat middle cerebral artery occlusion model was designed to assess neuroprotective effects of stroke pretreated MSCs on cerebral ischemia/reperfusion injury." | ( Huang, J; Lin, L; Lv, X; Shen, Y; Tang, W; Wang, B; Yao, Y, 2022) |
| "Mice subjected to transient middle cerebral artery occlusion (tMCAO) or sham surgery were treated with α7nAChR agonist AR-R17779 (12 mg/kg) or saline once daily for 5 days." | ( Darsalia, V; Hammarlund, ME; Johansson, ME; Mallard, C; Mjörnstedt, F; Patrone, C; Pattanaik, B; Rocha-Ferreira, E, 2021) |
| "Rats or neurons before middle cerebral artery occlusion/reperfusion (MCAO/R) or oxygen-glucose deprivation/reoxygenation (OGD/R) injury were pretreated with resveratrol." | ( Fan, C; Guo, S; Liao, H; Tang, F; Wang, L; Yang, Q; Yu, P, 2021) |
| "In this study, we treated a diabetic middle cerebral artery occlusion mouse model with ISO." | ( Guo, WJ; Hong, P; Huang, XX; Li, FX; Lin, HB; Tang, ZY; Wang, JW; Xu, SY; Zhang, HF; Zhang, YJ, 2022) |
| "Rats were subjected to middle cerebral artery occlusion (MCAO) and allocated randomly to TGN 020-treated and control groups." | ( Hao, X; Li, C; Lin, L; Ren, Y; Sun, C; Tian, J; Yang, Y; Yin, L; Zhang, X, 2022) |
| "Rats who received middle cerebral artery occlusion surgery (MCAO) were treated with SGD for 3 or 6 days, to investigate the therapeutic effect and the underlying mechanism of SGD for cerebral ischemia-reperfusion injury (CI/RP)." | ( Cui, R; Ding, H; Lu, J; Wang, J; Yan, G; Yu, L; Zhang, Y, 2022) |
| "Subjects underwent permanent middle cerebral artery occlusion; pial collateral recruitment was scored before treatment." | ( Carroll, T; Christoforidis, GA; Jeong, YI; Liu, M; Niekrasz, M; Roth, S; Saadat, N, 2023) |
| "First, middle cerebral artery occlusion (MCAO) model rats were treated with FFDZT." | ( Cheng, T; Gu, Y; Huang, P; Li, H; Liu, A; Sun, Y; Wu, G; Yang, J; Ye, J; Zhao, J, 2022) |
| "Male SD rats were performed to establish middle cerebral artery occlusion (MCAO) model injected with 50% high glucose (HG) and HUVECs were subjected to OGD/R treated with high glucose (30 mM) for establishing HT model in vivo and in vitro." | ( Guo, Y; Han, S; He, P; Li, M; Liu, C; Tian, Q; Wang, G; Wang, J; Wei, H; Yang, C, 2023) |
| "In the middle cerebral artery occlusion-reperfusion (MCAO/R) mice model or oxygen-glucose deprivation/reperfusion (OGD/R) cell model, Fer-1, AA9, and/or ML385 were administered, and brain infarct size, neurological deficits, neuronal damage, oxidative stress, and neuroinflammation were determined after the damage, in vitro and in vivo." | ( Chang, C; Chen, Y; He, W; Long, T; Meng, J; Wei, H; Xu, Q; Yang, L; Zhang, C, 2023) |
| "Cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) surgery and retinoic acid (5 mg/kg) or vehicle was administered to adult male rats for four days prior to surgery." | ( Kang, JB; Koh, PO, 2023) |
| "Here, CIRI was induced by middle cerebral artery occlusion-reperfusion (MCAO/R) in C57BL/6 J mice and modelled by oxygen and glucose deprivation/reoxygenation (OGD/R) in HT22 cells, it was treated with or without Biliverdin." | ( Bai, W; Huo, S; Li, J; Shao, J; Yang, Y; Zhou, G, 2023) |
| "After Atglistatin treatment, middle cerebral artery occlusion (MCAO) mice showed decreased infarct volume and improved neurobehavioral performance at the acute stage of stroke." | ( Bao, X; Cao, X; Deng, S; Li, H; Liu, P; Xia, S; Xu, Y; Zhang, B; Zhu, L, 2023) |